Promising Activity in MSS CRC with Innovative Drug Combined with Bevacizumab and Chemotherapy
January 20th 2024In the DeFianCe trial, the combination of DKN-01 with bevacizumab and chemotherapy is being investigated to assess the potential clinical benefits for patients diagnosed with microsatellite stable colorectal adenocarcinoma.
Read More
First-Line Nivolumab Plus Ipilimumab Demonstrates Superior PFS in mCRC
January 20th 2024Results from the phase 3 CheckMate-8HW trial support first-line treatment with nivolumab plus ipilimumab as a standard-of-care option for patients with microsatellite instability–high or mismatch repair deficient metastatic colorectal cancer.
Read More
Regorafenib Discontinuation More Likely With Poor Liver Function in Liver Cancer
January 19th 2024Patients with unresectable hepatocellular carcinoma and poor liver function were more likely to experience serious adverse effects leading to regorafenib treatment discontinuation, researchers have found.
Read More
Pembrolizumab Plus Lenvatinib Shows ‘Encouraging’ DOR in Advanced HCC
January 19th 2024The frontline use of pembrolizumab plus lenvatinib in patients with advanced HCC showed a 3-year or more response among 35% of responders; however, additional efficacy results remained consistent with previous findings from the phase 3 LEAP-002 trial.
Read More
Optimal Results: Neoadjuvant Durvalumab and Chemotherapy Drive Improvement in Gastric/GEJ Cancers
January 19th 2024The combination of neoadjuvant FLOT with durvalumab demonstrated enhanced pathological complete response compared to sole chemotherapy in individuals with resectable gastric and GEJ cancers, regardless of geographical location.
Read More
Tiragolumab, Atezolizumab, and Chemotherapy Combo Boosts Survival in ESCC
January 19th 2024An immunotherapy combination with chemotherapy significantly extended survival and delayed cancer progression in patients with esophageal squamous cell carcinoma compared with standard chemotherapy alone.
Read More
Optimal Outcomes: Nivolumab Plus Chemotherapy Boosts Survival Rates
January 18th 2024In patients who were administered nivolumab in conjunction with chemotherapy, there were enhancements observed in both overall survival and progression-free survival compared to those who received chemotherapy alone.
Read More
Enhanced Effectiveness Noted in Nivolumab Combination for Advanced GI Cancers
January 18th 2024Findings from an observational investigation revealed that the combination of nivolumab and chemotherapy contributed to improve survival in individuals diagnosed with advanced gastrointestinal cancers.
Read More
Zanubrutinib Preferred Over Bendamustine/Rituximas Across CLL/SLL Subgroups
December 15th 2023Treatment with zanubrutinib conferred a PFS benefit vs bendamustine plus rituximab across most biomarker subgroups of patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without del(17p), according to findings from the phase 3 SEQUOIA trial.
Read More
Responses With Pirtobrutinib Still High Even With Acquired Resistance in Relapsed CLL/SLL
December 13th 2023Responses on the non-covalent BTK inhibitor pirtobrutinib remained high in patients with relapsed chronic lymphocytic leukemia who expressed frequent baseline BTK mutations, according to a genomic analysis of the phase 1/2 BRUIN trial.
Read More
DZD8586 Shows Responses Across Dosages in B-Cell Non-Hodgkin Lymphoma
December 13th 2023DZD8586 showcased antitumor activity and favorable safety with limited grade 3 or greater treatment-emergent adverse effects in patients with heavily pretreated B-cell non-Hodgkin lymphoma, according to preliminary findings from a pooled analysis of two ongoing phase 1 trials.
Read More